Influenza antiviral agents play important roles in modulating disease severity and in controlling pandemics while vaccines are prepared, but the development of resistance to agents like the commonly used neuraminidase inhibitor oseltamivir may limit their future utility. We report here on a new class of specific, mechanism-based anti-influenza drugs that function through the formation of a stabilized covalent intermediate in the influenza neuraminidase enzyme, and we confirm this mode of action with structural and mechanistic studies. These compounds function in cell-based assays and in animal models, with efficacies comparable to that of the neuraminidase inhibitor zanamivir and with broad-spectrum activity against drug-resistant strains in vitro. The similarity of their structure to that of the natural substrate and their mechanism-based design make these attractive antiviral candidates.
The purpose of this work was to characterize the solid-state properties of anhydrous paclitaxel and paclitaxel dihydrate. Paclitaxel I (anhydrous) was suspended in water for 24 h to convert it to paclitaxel.2H2O. Both forms were analyzed by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). X-ray powder diffraction (XRPD) patterns were obtained at 25, 100, and 195 degrees C. Dissolution profiles of both forms were obtained in water at 37 degrees C over h. DSC of paclitaxel.2H2O showed two endothermic peaks below 100 degrees C, corresponding to dehydration. The resulting solid phase was termed "dehydrated paclitaxel.2H2O". At 168 degrees C, a solid-solid transition was observed in which dehydrated paclitaxel.2H2O was converted to a semicrystalline material called "paclitaxel I/am". The solid-solid transition was followed by melting at 220 degrees C. TGA of paclitaxel.2H2O showed a corresponding biphasic weight loss below 100 degrees C, which was equivalent to the weight of 2 mol of water. DSC of paclitaxel I showed no transitions before melting at 220 degrees C, and no weight loss was observed by TGA. Quenching of paclitaxel I from the melt produced amorphous paclitaxel with a glass transition at 152 degrees C. XRPD confirmed that paclitaxel I, paclitaxel.2H2O, and dehydrated paclitaxel.2H2O had different crystal structures. The X-ray patterns of paclitaxel I and paclitaxel I/am were similar, however the two forms of paclitaxel did not behave identically when analyzed by DSC. The bulk dissolution studies with paclitaxel I showed a rapid increase in concentration to 3 micrograms/mL in 4 h, which decreased to 1 microgram/mL after 12 h, corresponding to the solubility of paclitaxel.2H2O. The solubility of paclitaxel.2H2O was 1 microgram/mL. The data demonstrate the existence of a dihydrate form of paclitaxel that is the stable form in equilibrium with water at 37 degrees C but which dehydrates at temperatures > 45 degrees C.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.